Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.
Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to oral gildeuretinol acetate (ALK-001; Alkeus Pharmaceuticals) for Stargardt disease, according to a 24 August announcement from Alkeus Pharmaceuticals. The designation may provide development incentives but does not establish the investigational drug's efficacy or safety and is not marketing approval.¹
Byron Lam, MD, of Bascom Palmer Eye Institute, said, 'the designation reflects growing international recognition of the unmet need in Stargardt disease', noting that Japanese regulators typically seek data from Japanese participants in a multicentre trial, although the number required may be limited.
Japan's orphan framework applies to drugs intended for diseases affecting fewer than 50,000 people nationally and for which medical need is considered high. According to Alkeus, designation can confer eligibility for development subsidies and, if the product ultimately receives approval, up to 10 years of market exclusivity.¹ The action does not indicate that the MHLW has completed a benefit-risk review. No phase 3 efficacy or safety findings accompanied the announcement, and Alkeus did not provide a timetable for a Japanese marketing application.
Gildeuretinol previously received breakthrough therapy, fast track, rare paediatric disease, and orphan drug designations for Stargardt disease from the US FDA, according to the company. The European Medicines Agency has designated it an orphan medicinal product for nonsyndromic inherited retinal dystrophies caused by ABCA4 defects, a category that includes Stargardt disease.¹ The drug remains investigational in these jurisdictions.
• Drug: Gildeuretinol acetate (ALK-001)
• Class: Oral vitamin A–based NME
• Indication: Stargardt disease
• Trial: Phase 3 NORTHSTAR
• Primary end point: Atrophy growth rate
• Efficacy: No phase 3 results reported
• Safety: No phase 3 findings reported
• Status: Japan orphan designation
• Approval: Not approved for marketing
NORTHSTAR is a randomised, placebo-controlled, double-masked, 24-month phase 3 trial evaluating gildeuretinol in patients with advanced Stargardt disease. The sponsor plans to enrol approximately 230 participants aged 8 to 45 years at sites globally.1,2
The primary end point is the rate of retinal atrophic lesion growth from months 6 through 24 with gildeuretinol compared with placebo. The key secondary end point is preservation of low-luminance visual acuity.1,2 These measures address both structural disease progression and visual function, although the extent to which changes in lesion growth will correspond to patient-relevant functional benefit remains to be determined.
Alkeus stated that the phase 3 programme builds on experience in more than 400 patients treated with gildeuretinol. However, the announcement did not provide comparative outcomes, adverse-event rates, discontinuation data, or detailed findings from those earlier exposures.¹
Stargardt disease is an inherited, progressive macular disorder that commonly begins during childhood, adolescence, or early adulthood. It damages central vision and can impair reading, facial recognition, driving, and independent daily activities. Alkeus cited an estimated worldwide prevalence of approximately 1 in 8000 to 10,000 people.¹ There are no FDA-approved therapies for Stargardt disease. Management therefore focuses on diagnosis, monitoring, low-vision support, and rehabilitation rather than an approved treatment proven to slow retinal atrophy.¹
Lam said confirming a genetic diagnosis early is playing a growing role in identifying ABCA4-related Stargardt disease and flagging which patients may qualify for trials and future approved therapies. 'Testing and counselling can be coordinated by an inherited retinal disease specialist or a retina specialist experienced in genetic testing', he said, noting that referring patients sooner keeps them from missing windows to enrol in studies and helps move new treatments forward.
Gildeuretinol is an oral new molecular entity designed to reduce vitamin A dimerisation without modulating the visual cycle, according to Alkeus.¹ The therapeutic rationale is to reduce formation of vitamin A dimers implicated in retinal pathology while preserving visual-cycle function.
Lam explained that gildeuretinol works by limiting the buildup of harmful vitamin A byproducts, known as bisretinoids, rather than by blocking the visual cycle itself, setting it apart from therapies that cut down how much vitamin A reaches the retina or that target the disease at the gene level. He called it 'a distinct strategy aimed at slowing the toxic accumulation that contributes to retinal degeneration'.
The placebo-controlled, double-masked design of NORTHSTAR should permit a more rigorous assessment than uncontrolled experience. The designation itself cannot predict clinical benefit and important outstanding questions include the magnitude and durability of any reduction in atrophic lesion growth, effects on everyday visual function, oral treatment adherence, and longer-term systemic and ocular safety.
Lam said the trial's placebo-controlled design should finally clarify whether gildeuretinol actually slows retinal atrophy and whether it's safe over time. He said the bigger unknowns are how large and lasting any treatment effect turns out to be, and whether it works differently depending on how advanced a patient's disease is or what their lesions look like. Where gildeuretinol ultimately fits among the other Stargardt therapies in the pipeline, he said, is a question that will only get answered once those comparisons can be made.
